SE9903619D0 - Use and method of treatment - Google Patents
Use and method of treatmentInfo
- Publication number
- SE9903619D0 SE9903619D0 SE9903619A SE9903619A SE9903619D0 SE 9903619 D0 SE9903619 D0 SE 9903619D0 SE 9903619 A SE9903619 A SE 9903619A SE 9903619 A SE9903619 A SE 9903619A SE 9903619 D0 SE9903619 D0 SE 9903619D0
- Authority
- SE
- Sweden
- Prior art keywords
- immune responses
- mediated immune
- cell mediated
- patient
- excessive
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 4
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 210000000447 Th1 cell Anatomy 0.000 abstract 2
- 210000004241 Th2 cell Anatomy 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 abstract 2
- 201000008827 tuberculosis Diseases 0.000 abstract 2
- 235000008210 xanthophylls Nutrition 0.000 abstract 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 241000195493 Cryptophyta Species 0.000 abstract 1
- 241000168525 Haematococcus Species 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 208000024340 acute graft versus host disease Diseases 0.000 abstract 1
- 235000013793 astaxanthin Nutrition 0.000 abstract 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 abstract 1
- 229940022405 astaxanthin Drugs 0.000 abstract 1
- 239000001168 astaxanthin Substances 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract 1
- 229960005375 lutein Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 abstract 1
- 150000003735 xanthophylls Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9903619A SE9903619D0 (sv) | 1999-10-07 | 1999-10-07 | Use and method of treatment |
| EP00970399A EP1217996A1 (en) | 1999-10-07 | 2000-10-05 | Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections |
| PCT/SE2000/001923 WO2001024787A1 (en) | 1999-10-07 | 2000-10-05 | Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections |
| AU79788/00A AU780797B2 (en) | 1999-10-07 | 2000-10-05 | Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections |
| CA002388785A CA2388785A1 (en) | 1999-10-07 | 2000-10-05 | Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections |
| US10/088,496 US6773708B1 (en) | 1999-10-07 | 2000-10-05 | Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections |
| JP2001527786A JP5005143B2 (ja) | 1999-10-07 | 2000-10-05 | 自己免疫疾患、慢性ウイルス性および細胞内細菌性感染症の治療のためのアスタキサンチン等のキサントフイルの使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9903619A SE9903619D0 (sv) | 1999-10-07 | 1999-10-07 | Use and method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE9903619D0 true SE9903619D0 (sv) | 1999-10-07 |
Family
ID=20417279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9903619A SE9903619D0 (sv) | 1999-10-07 | 1999-10-07 | Use and method of treatment |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6773708B1 (sv) |
| EP (1) | EP1217996A1 (sv) |
| JP (1) | JP5005143B2 (sv) |
| AU (1) | AU780797B2 (sv) |
| CA (1) | CA2388785A1 (sv) |
| SE (1) | SE9903619D0 (sv) |
| WO (1) | WO2001024787A1 (sv) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0314624D0 (en) | 2003-06-23 | 2003-07-30 | Advanced Bionutrition Europ Lt | Inflammatory disease treatment |
| WO2005058064A1 (ja) * | 2003-12-19 | 2005-06-30 | Menicon Co., Ltd. | アスタキサンチン配合ペット用食物 |
| EP2653157B1 (en) * | 2004-02-04 | 2016-08-03 | Fuji Chemical Industry Co., Ltd. | Astaxanthin for improving muscle atrophy |
| KR101327590B1 (ko) | 2004-09-28 | 2013-11-12 | 체마폴, 인코포레이티드. | 체중 증가 및 사료 전환을 촉진하는 조성물 및 방법 |
| JP2007238441A (ja) * | 2004-12-03 | 2007-09-20 | Fuji Chem Ind Co Ltd | アスタキサンチンを有効成分とする体脂肪減少用組成物 |
| GB0501365D0 (en) * | 2005-01-21 | 2005-03-02 | Promar As | Compositions |
| JP2006008714A (ja) * | 2005-03-17 | 2006-01-12 | Yamaha Motor Co Ltd | マトリックスメタロプロテイナーゼ阻害剤 |
| JP2006008718A (ja) * | 2005-06-03 | 2006-01-12 | Yamaha Motor Co Ltd | シクロオキシゲナーゼ活性阻害剤 |
| JP2006008719A (ja) * | 2005-06-23 | 2006-01-12 | Yamaha Motor Co Ltd | 血中過酸化脂質抑制剤 |
| EP1904070A4 (en) * | 2005-07-07 | 2009-09-02 | H3 Formulations Ltd | NUTRITIONAL SUPPLEMENT FOR IMPROVING SKELETAL MUSHROOMS, REDUCING MUSCLE PROTEIN DEGRADATION, DOWNGRADING MUSCLE CATABOLISM PATHS, AND REDUCING CATABOLISM OF MUSCLE CELLS |
| AU2006318357B2 (en) * | 2005-11-28 | 2009-09-24 | U.S. Nutraceuticals Llc Dba Valensa International | Algal and algal extract dietary supplement composition |
| JP2007153845A (ja) * | 2005-12-07 | 2007-06-21 | Yamaha Motor Co Ltd | 脂肪蓄積抑制剤 |
| US20070135521A1 (en) * | 2005-12-14 | 2007-06-14 | Yamaha Hatsudoki Kabushiki Kaisha | Agent for Preventing Metabolic Syndrome |
| JP2007254411A (ja) * | 2006-03-24 | 2007-10-04 | Tokyo Univ Of Pharmacy & Life Science | アグリカナーゼ産生阻害剤 |
| US20070293568A1 (en) | 2006-06-16 | 2007-12-20 | Yamaha Hatsudoki Kabushiki Kaisha | Neurocyte Protective Agent |
| NZ585620A (en) | 2007-10-26 | 2013-03-28 | Ca Nat Research Council | Compositions and methods for enhancing immune response |
| WO2010124392A1 (en) * | 2009-04-30 | 2010-11-04 | Chemaphor Inc. | Methods, compositions, and kits for the treatment of inflammatory conditions |
| WO2010124391A1 (en) | 2009-04-30 | 2010-11-04 | Chemaphor Inc. | Methods and compositions for improving the health of animals |
| JP6580895B2 (ja) * | 2014-08-08 | 2019-09-25 | 株式会社コーセー | アスタキサンチン含有デスモグレイン減少剤 |
| US9572783B1 (en) | 2015-10-08 | 2017-02-21 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
| EP3153160B1 (en) | 2015-10-08 | 2021-08-11 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
| CN113749050A (zh) * | 2020-06-04 | 2021-12-07 | 温州医科大学 | 虾青素提取物治疗2型糖尿病的方法与系统 |
| IT202000032402A1 (it) * | 2020-12-24 | 2022-06-24 | Innobio S R L | Composizione immunostimolante per indurre una risposta immunitaria |
| AU2022224703A1 (en) | 2021-09-28 | 2023-04-13 | Samuel L. Shepherd | Tetraterpenes for use in cancer therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2619491B2 (ja) * | 1988-08-11 | 1997-06-11 | サントリー株式会社 | アスタキサンチン含有組成物 |
| JPH05124958A (ja) * | 1991-09-19 | 1993-05-21 | Yukio Date | 過酸化脂質低下作用を有する組成物 |
| JPH05339148A (ja) * | 1992-05-28 | 1993-12-21 | T Knight Albert | 血液脳関門を通過する物質 |
| JPH07300421A (ja) * | 1994-04-28 | 1995-11-14 | Itano Reitou Kk | 抗炎症剤 |
| SE503336C2 (sv) * | 1994-09-19 | 1996-05-28 | Asta Carotene Ab | Medel och sätt för att öka produktionen av/hos fjäderfän |
| EP0806946A2 (de) * | 1995-02-03 | 1997-11-19 | Basf Aktiengesellschaft | Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen |
| SE522246C2 (sv) * | 1997-02-27 | 2004-01-27 | Astacarotene Ab | Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion |
| US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
| SE511237C2 (sv) * | 1997-12-16 | 1999-08-30 | Astacarotene Ab | Användning av åtminstone en typ av xantofyller för framställning av ett humant eller verinärmedicinskt läkemedel för profylaktisk behandling av mastit hos däggdjursmammor |
-
1999
- 1999-10-07 SE SE9903619A patent/SE9903619D0/sv unknown
-
2000
- 2000-10-05 WO PCT/SE2000/001923 patent/WO2001024787A1/en not_active Ceased
- 2000-10-05 US US10/088,496 patent/US6773708B1/en not_active Expired - Lifetime
- 2000-10-05 JP JP2001527786A patent/JP5005143B2/ja not_active Expired - Fee Related
- 2000-10-05 CA CA002388785A patent/CA2388785A1/en not_active Abandoned
- 2000-10-05 AU AU79788/00A patent/AU780797B2/en not_active Ceased
- 2000-10-05 EP EP00970399A patent/EP1217996A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2388785A1 (en) | 2001-04-12 |
| JP5005143B2 (ja) | 2012-08-22 |
| AU780797B2 (en) | 2005-04-21 |
| US6773708B1 (en) | 2004-08-10 |
| JP2003510353A (ja) | 2003-03-18 |
| AU7978800A (en) | 2001-05-10 |
| EP1217996A1 (en) | 2002-07-03 |
| WO2001024787A1 (en) | 2001-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE9903619D0 (sv) | Use and method of treatment | |
| Lohmann‐Matthes et al. | Macrophage‐mediated cytotoxicity against allogeneic target cells in vitro | |
| CUNNINGHAM | New culture medium for maintenance of tsetse tissues and growth of trypanosomatids | |
| KR101578591B1 (ko) | 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
| CN105154395B (zh) | 一种增强MSCs免疫调节功能的临床级别细胞制备方法 | |
| CN102994449A (zh) | 一种体外扩增nk细胞的方法 | |
| ATE153856T1 (de) | Zusammensetzung zur stimulierung des immunsystems | |
| WO2004012759B1 (de) | Erythropoetin zur stimulation endothelialer voläuferzellen | |
| AU6649996A (en) | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease | |
| RU2008131300A (ru) | Длительное высвобождение нейрегулина для улучшения сердечной функции | |
| KR101900664B1 (ko) | 자가면역 및 염증성 질환에서 림프내 투여를 위한 지방-유래 중간엽 줄기 세포 | |
| GR3017535T3 (en) | Live vaccines. | |
| RU2005105065A (ru) | Стволовые кроветворные клетки и способы лечения с их помощью глазных болезней, связанных с новообразованием сосудов | |
| CA2314170A1 (en) | Method of the prophylactic treatment of mastitis | |
| CN109893542A (zh) | 用于治疗勃起功能障碍的干细胞外泌体浓缩液凝胶制剂及其制备方法与给药方法 | |
| IL257929B2 (en) | Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy | |
| CA3255126A1 (en) | NATURAL KILLER CELLS PRODUCED FROM INDUCED MULTIPOTENC STEM CELLS, THEIR PRODUCTION PROCESS AND THEIR USE | |
| WO2023007244A1 (en) | Mammalian cell population useful in cell therapy | |
| ATE269065T1 (de) | Behandlung von verdauungsstörungen | |
| CN106344612A (zh) | 一种用于治疗自身免疫性皮肤病的外用药物及其制备方法和应用 | |
| CN106344613A (zh) | 一种nk细胞原液在制备治疗皮肤病药物中的应用 | |
| ATE128964T1 (de) | Anwendung von beta-alethin in zellkultur und therapie. | |
| Mozes et al. | Increased interferon production in human cells irradiated with ultraviolet light | |
| CANTELL et al. | IFN-γ enhances production of IFN-α in human macrophages but not in monocytes | |
| ИММУНОСТИМУЛИРУЮЩАЯ et al. | Anticancer and immunostimulatory effects of nucleoprotein fraction of Bacillus subtilis 7025 culture medium filtrate |